Every Form 4 that Insmed, Inc. (INSM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INSM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INSM filings page.
INSMED Inc (INSM) director David R. Brennan reported selling 25,000 shares of common stock on September 9, 2026 in a sale described as an open market or private transaction at $124.00 per share. Following this sale, he directly holds 39,238 shares of INSMED common stock.
The filing also reports indirect ownership of 60,000 shares held through a spouse revocable trust as of the same date. No Rule 10b5-1 trading plan is reported for these transactions.
INSMED Inc (INSM) director Melvin Sharoky, MD reported an indirect sale of 5,000 shares of common stock on 2026-08-17 through Padonia, LLC at a weighted average price of $127.53 per share, within a range of $127.51–$127.61. After this transaction Padonia, LLC held zero shares. Dr. Sharoky continues to hold 246,081 shares directly, and additional shares are held indirectly through his spouse and several UTMA/FL custodial accounts for family members, for which he serves as custodian.
INSMED Inc Chief Operating Officer Roger Adsett reported multiple option exercises and a same‑day share sale. He exercised three stock option grants covering a total of 239,850 shares of common stock at exercise prices of $13.67, $17.16, and $30.46 per share, with the options fully vested under a stated vesting schedule. He then sold 239,850 shares of common stock at a weighted average price of $133.27 per share, within a price range of $133.00–$133.51. One acquisition line also notes inclusion of 141 shares from the company’s 2018 Employee Stock Purchase Plan.
Insmed Inc’s Chief Medical Officer, Martina Flammer, exercised stock options for 27,173 shares of common stock on August 6, 2026 and sold the same number of shares, in transactions effected under a Rule 10b5-1 trading plan adopted on February 27, 2025.
The options covered 18,278 shares at $18.95 and 8,895 shares at $25.83. Related sales were 8,895 shares at $127.00 and 18,278 shares at a weighted average $129.40 within a $129.40–$129.41 range.
INSMED Inc Chair and CEO William Lewis exercised stock options for 10,700 shares of common stock on July 23, 2026, at exercise prices of $30.46 and $17.16, then sold 10,700 shares at weighted average prices of $105.62 and $106.43 under a Rule 10b5-1 trading plan adopted on September 4, 2025. He continues to hold 233,924 shares indirectly through a trust.
INSMED Inc Chair and CEO William Lewis reported a series of equity transactions in company common stock. He exercised stock options covering 10,699 shares at exercise prices of $17.16 and $30.46 per share and sold 10,699 shares of common stock in multiple open-market transactions at prices ranging from approximately $116.01 to $118.80 per share. The sales were effected pursuant to a pre-established Rule 10b5-1 trading plan. Lewis also reports 233,924 shares of common stock held indirectly by a trust.
INSMED Inc's Chief Medical Officer, Martina Flammer, reported an exercise-and-sell transaction in company stock. She exercised stock options to acquire a total of 12,302 shares of common stock at strike prices of $19.74 and $29.13 per share, then sold the same 12,302 shares in open-market trades at weighted average prices of $110.60 and $109.02 per share. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025, and she now holds 60,486 shares of common stock directly.
INSMED Inc Chair and CEO William Lewis reported option exercises and share sales in INSMED common stock. On June 25, 2026, he exercised stock options covering 21,398 shares at strike prices of $17.16 and $30.46 per share, converting derivative awards into common stock.
On the same date, he sold 21,398 shares in multiple open-market transactions at weighted average prices ranging from about $101.78 to $106.45 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, Lewis holds 258,917 shares directly and 233,924 shares indirectly through a trust.
INSMED Inc senior vice president Samuele Butera received new equity awards as part of his compensation. He was granted 7,342 Restricted Stock Units, each representing one future share of common stock, with 25% vesting on the first day of the first month after the first anniversary of grant and the remainder vesting in three annual installments.
He was also granted stock options for 12,570 shares of common stock at an exercise price of $102.15 per share, expiring on June 23, 2036. These options vest 25% on the initial vesting date and 12.5% every six months thereafter until fully vested. All awards were granted for no cash consideration.
INSMED Inc Chief Legal Officer Michael Alexander Smith sold 1,806 shares of Common Stock in an open-market transaction. The shares were sold at a price of $95.82 per share. After this sale, he directly holds 37,648 shares of INSMED Inc Common Stock.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which means the timing and amount were set in advance rather than decided at the moment of sale.
INSMED Inc Chair and CEO William Lewis reported an open-market sale of 6,515 shares of Common Stock. The shares were sold at a price of $94.03 per share. After this transaction, he directly holds 258,917 shares of Common Stock.
The filing also shows an indirect holding of 233,924 shares of Common Stock held by a trust. According to a footnote, the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, indicating it was scheduled in advance.
INSMED Inc Chief Operating Officer Roger Adsett reported a sale of 2,370 shares of common stock. The shares were sold at an average price of $102.27 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units and to cover associated broker fees. After this transaction, Adsett directly holds 98,603 shares of INSMED common stock, indicating this was a routine, tax-driven disposition rather than a discretionary reduction in his equity stake.
Insmed Inc.’s Chief Financial Officer Sara Bonstein reported an automatic sale of shares tied to equity compensation. On the reported date, 2,404 shares of common stock were sold at $102.27 per share. According to the footnote, the shares were sold to satisfy tax withholding obligations when Restricted Stock Units vested and to cover related broker fees, rather than as a discretionary portfolio move. After this transaction, Bonstein directly owned 69,082 Insmed shares, so the filing mainly reflects routine tax handling on stock-based compensation.
INSMED Inc Chief Legal Officer Michael Alexander Smith reported an open-market sale of company stock mainly to cover taxes on vesting equity.
He sold 2,159 shares of Common Stock at $102.27 per share to satisfy tax withholding obligations from vested Restricted Stock Units and related broker fees. After this transaction, he directly holds 39,454 shares, so the sale represents only a portion of his overall stake and is characterized as a tax-related, administrative transaction rather than a discretionary reduction in ownership.
INSMED Inc Chair and CEO William Lewis reported an insider transaction involving company common stock. On June 3, 2026, he sold 7,605 shares of common stock at $102.27 per share. According to the footnote, these shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees, meaning this was a tax-related sale rather than a discretionary trade. Following the transaction, Lewis held 265,432 shares directly and 233,924 shares indirectly through a trust.
Insmed Inc.’s Chief Medical Officer, Dr. Martina Flammer, reported two small open-market sales of common stock made to cover taxes on equity compensation. She sold 2,566 shares at $102.27 on June 3 and 1,858 shares at $103.78 on June 5, totaling 4,424 shares. After these transactions, she directly holds 60,486 shares of Insmed common stock. The footnotes state the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and related broker fees, and that the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025.
INSMED Inc Chief Legal Officer Michael Alexander Smith reported an open-market sale of 6,149 shares of common stock at $108.47 per share. The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following this sale, he directly holds 41,613 company shares.
INSMED Inc Chair and CEO William Lewis reported a mix of stock sales and option exercises in company common stock. On May 18, 2026, he sold a total of 25,564 shares in three open-market transactions at weighted average prices in the $105–$107 per share range, executed under a preset Rule 10b5-1 trading plan adopted on September 4, 2025.
On the same date, Lewis also exercised 10,699 stock options to acquire common shares, with exercise prices of $17.16 and $30.46 per share. The filing shows both direct holdings and additional shares held indirectly through a trust, indicating he retains a substantial ownership interest after these transactions.
INSMED Inc Chief Financial Officer Sara Bonstein reported an open-market sale of 8,272 shares of common stock on May 13, 2026 at an average price of $116.18 per share. According to the filing, the shares were sold to satisfy tax withholding obligations and related broker fees arising from the vesting of Restricted Stock Units. After this transaction, Bonstein directly holds 71,486 shares of INSMED common stock, so the sale represents a relatively small portion of her overall reported holdings and is tied to compensation-related tax requirements rather than a discretionary portfolio change.
SCHAFER CAROL reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director Carol Schafer received an equity award of 3,305 Restricted Stock Units (RSUs) on May 13, 2026. Each RSU represents a contingent right to receive one share of common stock, granted for no cash consideration as part of director compensation.
The RSUs vest in full on the first anniversary of the grant date if she remains on the Board through the earlier of that date or the company’s annual shareholder meeting in that year, and attends at least 75% of Board meetings during the period. After this grant, she holds 66,622 shares of common stock directly.
INSMED Inc Chief Operating Officer Roger Adsett reported a small share sale primarily tied to taxes on equity compensation. He sold 5,837 shares of common stock at an average price of $116.18 per share. A footnote explains the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees, rather than as a discretionary portfolio move. After the transaction, he directly holds 100,973 shares of INSMED common stock.
ANDERSON ELIZABETH M reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director Elizabeth M. Anderson received a grant of 3,305 Restricted Stock Units (RSUs), each representing one share of common stock. The award was granted for no cash consideration.
The RSUs vest in full on the first anniversary of the May 13, 2026 grant date if she remains on the Board and attends at least 75% of Board meetings. Following the grant, she directly holds 62,034 shares.
INSMED Inc Chief Medical Officer Martina Flammer sold 18,333 shares of common stock in open-market transactions. The sales occurred on May 13 and May 14, 2026 at prices around $112.76 to $117.54 per share. After these trades, she directly holds 64,910 shares. Footnotes explain that shares were sold to satisfy tax withholding obligations on vested Restricted Stock Units and that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
INSMED Inc Chief Legal Officer Michael Alexander Smith reported an open-market sale of 4,109 shares of common stock at an average price of $116.18 per share. According to the filing, the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Following this tax-related sale, Smith directly holds 47,762 shares of INSMED common stock.
SHAROKY MELVIN MD reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director Melvin Sharoky received 3,305 Restricted Stock Units (RSUs) of Common Stock as a grant. The RSUs were granted on May 13, 2026 for no cash consideration and vest in full on the first anniversary of the grant date, subject to continued Board service and meeting-attendance conditions.
After this grant, Sharoky directly holds 246,081 shares of Common Stock, in addition to several indirect holdings through custodial UTMA/FL accounts, an LLC, and his spouse.
Brennan David R reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director David R. Brennan reported new equity compensation and existing indirect holdings. He received 3,305 Restricted Stock Units (RSUs), each representing one share of common stock, granted on May 13, 2026 for no consideration. These RSUs vest in full on the first anniversary of the grant date if he remains on the Board and attends at least 75% of Board meetings during the vesting period. After the grant, he directly holds 64,238 shares of common stock and has an additional 60,000 shares held indirectly through his spouse’s revocable trust.
Desjardins Clarissa reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director Clarissa Desjardins reported a new equity award and updated holdings. She received a grant of 3,305 Restricted Stock Units (RSUs) of Common Stock on May 13, 2026 for no cash consideration. After this grant, she holds 70,312 shares of Common Stock directly and 3,025 shares indirectly through her spouse.
The RSUs represent a contingent right to receive one share of Common Stock each and vest in full on the first anniversary of the grant date. Vesting requires that she remain on the Board through the earlier of that anniversary or the company’s annual shareholder meeting in that year and attend at least 75% of Board meetings during the vesting period.
LEE LEO reported acquisition or exercise transactions in this Form 4 filing.
Insmed Inc director Leo Lee reported receiving a grant of 3,305 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 13, 2026 for no cash consideration. Each RSU represents a contingent right to one share and vests in full on the first anniversary of the grant date if he remains on the Board through the earlier of that date or the company’s Annual Shareholder Meeting in that year, and attends at least 75% of Board meetings during the period. After this grant and an 11‑share downward correction for a prior clerical error, Lee beneficially owns 57,971 shares directly.
INSMED Inc Chair and CEO William Lewis reported an insider transaction involving company Common Stock. On May 13, 2026, he sold 13,283 shares at $116.18 per share, with a footnote explaining the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and related broker fees.
Following this sale, Lewis held 287,902 shares of Common Stock directly and 233,924 shares indirectly through a trust, indicating he retains a substantial equity stake in INSMED after these tax-related transactions.
Insmed Inc.'s Chief Medical Officer, Martina Flammer, M.D., reported an exercise-and-sell transaction in company stock. She exercised stock options to acquire 12,949 shares of common stock at $17.07 per share, then sold 12,949 shares in open-market transactions at weighted average prices of $100.35 for 12,119 shares and $101.18 for 830 shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025. Following these transactions, she holds 83,243 shares of Insmed common stock directly.
Insmed Inc Chair and CEO William Lewis reported a series of routine equity transactions in the company’s common stock. On May 4, 2026, he sold 10,699 shares in multiple open-market trades at weighted average prices ranging from about $134 to $139.60 per share, executed under a Rule 10b5-1 trading plan adopted on September 4, 2025.
On the same date, he exercised stock options to acquire a total of 10,699 shares of common stock at exercise prices of $17.16 and $30.46 per share. The filing also reflects an indirect holding of 233,924 shares held by trust, indicating Lewis continues to maintain a significant ownership position in Insmed alongside these transactions.
INSMED Inc Chair and CEO William Lewis exercised stock options and sold shares in INSMED Inc. On April 16, 2026, he exercised options for 10,699 shares of Common Stock at exercise prices of $30.46 and $17.16 per share.
That same day he sold a total of 10,699 shares of Common Stock in open-market transactions at weighted average prices between $142.39 and $146.02 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions he directly held 301,185 shares, with an additional 233,924 shares held indirectly by a trust.
Insmed Inc Chair and CEO William Lewis reported option exercises and share sales in Insmed common stock. On April 6, 2026, he exercised stock options for a total of 10,699 shares at strike prices of $30.46 and $17.16 per share, then sold 10,699 shares in open-market transactions at weighted average prices around $161.73, $163.23, and $164.01. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly owned about 301,185 shares of common stock, with an additional 233,924 shares held indirectly through the Katie Procter Dynasty Trust.
Insmed Inc Chief Operating Officer Roger Adsett exercised options to acquire 88,060 shares of common stock at an exercise price of $14.56 per share. On the same date, he sold 88,060 shares in open-market transactions at weighted average prices of $163.18, $164.11, and $164.95 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Following these transactions, he directly holds 106,810 shares of Insmed common stock.
INSMED Inc Chief Legal Officer Michael Alexander Smith exercised stock options and sold shares in a pre-planned transaction. On March 30, 2026, he exercised options for 19,638 shares of common stock at exercise prices of $17.07 and $27.89 per share. The same day, he sold 19,638 shares of common stock at $150.98 per share under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he directly owned 51,871 shares of INSMED common stock.
INSMED Inc Chair and CEO William Lewis exercised stock options and sold shares in a planned transaction. On 2026-03-19, he exercised options for 10,699 shares of common stock at exercise prices of $30.46 and $17.16 per share, converting them into common shares.
That same day, he sold 10,699 shares of common stock in open-market trades at weighted average prices ranging from about $141.80 to $144.72, under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, he directly holds 301,185 shares, plus 233,924 shares held indirectly through the Katie Procter Dynasty Trust.
INSMED Inc Chair and CEO William Lewis reported multiple transactions in company stock. On 2026-03-05, he exercised stock options for 6,259 and 4,440 shares of common stock through derivative conversions. He then sold a total of 10,699 common shares in open-market transactions at weighted average prices noted in the filing, effected under a Rule 10b5-1 trading plan adopted on September 4, 2025. After these trades, he held 301,185 common shares directly and 233,924 common shares indirectly through the Katie Procter Dynasty Trust as of that date.
INSMED Inc director Melvin Sharoky, MD reported a bona fide gift of common stock. On March 3, 2026, an entity associated with him transferred 100 shares of common stock as a gift transfer at a reported price of $0.0000 per share, reducing his directly held shares to 242,776.
He also reported several indirect holdings: 6,847 shares held by his spouse, 5,000 shares held by Padonia, LLC, where he is the managing member, and custodial UTMA/FL accounts holding 819, 5,423, 5,007, and 3,724 shares for named family beneficiaries.
Insmed Inc director Melvin Sharoky reported several bona fide gifts of common stock dated February 25, 2026. He gifted 1,072 shares from his direct holdings and 243 shares to each of four UTMA custodial accounts for family members. After these gifts, he continued to hold 242,876 shares directly, while indirect holdings included shares in custodial UTMA accounts, 5,000 shares held through Padonia, LLC, and 6,847 shares held by his spouse.
Insmed Inc’s Chief Legal Officer, Michael Alexander Smith, reported option exercises and share sales in company stock. On February 24, 2026, he exercised a stock option for 20,248 shares, converting a derivative security into common stock at a reported price of $17.07 per share.
On the same date, he sold a total of 24,774 shares of common stock in open-market transactions at weighted average prices of $153.93, $155.06, and $156.53 per share, under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he directly owned 51,871 common shares of Insmed.
INSMED Inc director David R. Brennan reported a bona fide gift of 6,000 shares of Common Stock. The gift was made on February 23, 2026 at a reported price of $0.00 per share, indicating it was a non-cash, charitable or personal transfer rather than a sale.
After this disposition, Brennan directly holds 60,933 shares of INSMED Common Stock. In addition, an indirect holding of 60,000 shares is reported as being held by a spouse revocable trust, reflecting shares associated with, but not directly owned by, the director.
Insmed Inc Chair and CEO William Lewis reported option exercises and share sales. On February 19, 2026, he exercised stock options for 6,259 and 4,440 shares, converting them into an equal number of Common Stock shares at grant prices of $30.46 and $17.16 per share.
On the same date, he sold a total of 10,699 Common Stock shares in open-market transactions at weighted average prices between $149.17 and $153.38, under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 4, 2025. After these trades, he held 301,185 shares directly, plus indirect holdings of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
INSMED Inc. director David W. J. McGirr reported a bona fide gift transfer of 53,400 shares of common stock on February 9, 2026. The filing shows 53,400 shares moved from his direct holdings to indirect ownership through a family trust, leaving 44,323 shares held directly and 53,400 shares held indirectly.
INSMED Inc.’s Chair and CEO William Lewis reported option exercises and share sales on common stock. On February 9, 2026, he exercised stock options for 4,440 shares at $17.16 and 6,259 shares at $30.46 per share, converting them into common stock. The same day, he sold 4,888 shares at a weighted average price of $147.17, 7,221 shares at $148.02, and 1,287 shares at $148.83, under a Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, he directly owned 301,185 common shares and had indirect ownership of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
Insmed Inc.’s Chief Medical Officer, Martina Flammer, M.D., reported a planned stock sale. On 02/05/2026 she sold 869 shares of Insmed common stock at $152.44 per share in a transaction coded as a sale. After this trade, she beneficially owned 83,243 shares directly.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that she adopted on February 27, 2025. Such plans allow insiders to schedule trades in advance, helping separate routine portfolio moves from day-to-day corporate developments.
INSMED Inc.'s Chief Operating Officer Roger Adsett reported a routine sale of company stock in connection with equity compensation. On February 3, 2026, he sold 791 shares of common stock at a price of $156.17 per share. A footnote explains that the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees, rather than as a discretionary open-market sale. After this transaction, Adsett beneficially owned 106,810 shares of INSMED common stock directly.
Insmed Inc.'s Chief Financial Officer, Sara Bonstein, reported a small share sale under a Form 4 filing. On 02/03/2026, she sold 748 shares of Insmed common stock at a price of $156.34 per share. According to the filing, these shares were sold to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units and to cover related broker fees, rather than as a discretionary sale. After this transaction, Bonstein beneficially owned 79,758 shares of Insmed common stock directly.
Insmed Inc. Chair and CEO William Lewis reported a routine share sale linked to tax withholding. On February 3, 2026, he sold 3,009 shares of common stock at $156.34 per share to satisfy tax obligations from vested restricted stock units and related broker fees. After this sale, he directly owned 303,882 shares of Insmed common stock. In addition, he had indirect beneficial ownership of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
INSMED Inc's Chief Legal Officer reports a routine share sale related to equity compensation. On 02/03/2026, Michael Alexander Smith sold 640 shares of INSMED common stock at $156.27 per share. The filing explains the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. After this transaction, he directly beneficially owned 56,397 shares of common stock.
Insmed Inc.’s Chief Medical Officer Martina Flammer reported a series of stock transactions. On February 2, 2026, she exercised a stock option for 7,982 shares of common stock at $65.72 per share and sold multiple blocks of common stock under a Rule 10b5-1 trading plan, at weighted average prices including $152.06, $153.16, $154.56, $155.46 and $156.86 per share. On February 3, 2026, she sold 795 shares at $155.77 per share to satisfy tax withholding and related broker fees upon RSU vesting. After these transactions, she directly owned 84,112 shares of common stock and held 23,948 stock options.